SELECTED INVESTMENT · HEALTHCARE

Peloton Therapeutics

Specialist oncology research advancing a differentiated therapeutic approach.

Business overview

Peloton Therapeutics was a clinical-stage biopharmaceutical business developing small-molecule therapies targeting HIF-2α. Its lead candidate, PT2977, was being developed for renal cell carcinoma when the acquisition was announced.

Family investment

The family invested in Peloton Therapeutics and exited in 2019, the year of its acquisition by Merck.

Transaction & outcome

The acquisition agreement provided for $1.05 billion in upfront cash consideration and up to $1.15 billion in additional payments linked to regulatory and sales milestones. The milestone component was conditional rather than guaranteed.

Case perspective

This case highlights the relationship between scientific differentiation, clinical development and strategic demand from a pharmaceutical acquirer. Clinical and regulatory progress remain central considerations in this sector.